Tikiz H, Balbay Y, Atak R, Terzi T, Genç Y, Kütük E
Türkiye Yüksek Ihtisas Hospital, Department of Cardiology, Ankara, Turkey.
Clin Cardiol. 2001 Oct;24(10):656-62. doi: 10.1002/clc.4960241005.
Although there is increasing evidence for the beneficial effect of thrombolytic therapy on global left ventricular (LV) function in acute myocardial infarction (AMI), the data concerning the early effect of thrombolytic therapy on the incidence of left ventricular aneurysm (LVA) formation and its relationship to clinical and angiographic determinants are limited.
The study aimed to determine the independent factors involved in the development of LVA and to evaluate whether thrombolytic therapy has any preventive effect on the development of LVA in AMI.
In all, 350 consecutive patients suffering from a first attack of AMI were included. Of these, 205 who arrived within 12 h of onset of symptoms received thrombolytic therapy (thrombolytic group) and the remaining 145 patients served as control group. All patients received aspirin and maximal-dose anticoagulation with intravenous heparin therapy. Early successful reperfusion was assessed by enzymatic and electrocardiographic evidence, and late vessel patency was evaluated according to Thrombolysis in Myocardial Infarction (TIMI) classification. Patients with TIMI grade 2 or 3 flow were considered to have vessel patency.
The overall incidence of LVA was 11.7% (41/350), and no statistical difference was found between the incidence of LVA between the two groups (11.7 vs. 11.7%, p>0.05). However, the patients receiving thrombolytic therapy and exhibiting a patent infarct-related artery (PIRA) (n = 125, 61%), had a significantly reduced incidence of LVA compared with those who did not (7.2 vs. 18.8%, p= 0.015). In univariate analysis, vessel patency, proximal left anterior descending artery (LAD) stenosis, total LAD occlusion, multivessel disease, and hypertension were found to be important factors in LVA formation after AMI. After adjustment for other clinical and angiographic variables, total LAD occlusion (odds ratio [OR] 3.62,95% confidence interval [CI] 2.45-8.42, p = 0.0014), absence of PIRA (OR 2.92, 95% CI 1.41-09, p = 0.0037) and proximal LAD stenosis (OR 2.11, 95% CI 1.05-4.71, p = 0.045) remained the independent determinants of LVA formation after AMI.
Our data indicate that not all patients who received thrombolytic therapy, but only those with PIRA had evidently reduced the incidence of LVA. Patients with total LAD occlusion, with proximal LAD stenosis, and without PIRA were found to have increased risk for formation of LVA after AMI. These findings indicate that the presence of vessel patency has a preventive effect on LVA formation in AMI.
尽管越来越多的证据表明溶栓治疗对急性心肌梗死(AMI)患者的左心室(LV)整体功能有益,但关于溶栓治疗对左心室室壁瘤(LVA)形成发生率的早期影响及其与临床和血管造影决定因素之间关系的数据有限。
本研究旨在确定LVA发生发展的独立因素,并评估溶栓治疗对AMI患者LVA发生发展是否具有预防作用。
共纳入350例首次发作AMI的连续患者。其中,205例在症状发作后12小时内就诊的患者接受了溶栓治疗(溶栓组),其余145例患者作为对照组。所有患者均接受阿司匹林治疗,并静脉注射肝素进行最大剂量抗凝治疗。通过酶学和心电图证据评估早期再灌注成功情况,根据心肌梗死溶栓治疗(TIMI)分类评估晚期血管通畅情况。TIMI 2级或3级血流的患者被认为血管通畅。
LVA的总体发生率为11.7%(41/350),两组之间LVA的发生率无统计学差异(11.7%对11.7%,p>0.05)。然而,接受溶栓治疗且梗死相关动脉通畅(PIRA)的患者(n = 125,61%),与未通畅的患者相比,LVA的发生率显著降低(7.2%对18.8%,p = 0.015)。在单因素分析中,血管通畅、左前降支近端(LAD)狭窄、LAD完全闭塞、多支血管病变和高血压被发现是AMI后LVA形成的重要因素。在对其他临床和血管造影变量进行调整后,LAD完全闭塞(比值比[OR] 3.62,95%置信区间[CI] 2.45 - 8.42,p = 0.0014)、无PIRA(OR 2.92,95% CI 1.41 - 09,p = 0.0037)和LAD近端狭窄(OR 2.11,95% CI 1.05 - 4.71,p = 0.045)仍然是AMI后LVA形成的独立决定因素。
我们的数据表明,并非所有接受溶栓治疗的患者,只有那些有PIRA的患者LVA的发生率明显降低。发现LAD完全闭塞、LAD近端狭窄且无PIRA的患者在AMI后发生LVA的风险增加。这些发现表明血管通畅对AMI中LVA的形成具有预防作用。